Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbCellera Biologics Inc. - Common Shares (NQ: ABCL )

3.100 +0.170 (+5.80%)
Streaming Delayed Price Updated: 10:38 AM EST, Jan 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbCellera Biologics Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
3 Growth Stocks That Could Go Parabolic in 2024
These innovation-oriented companies could take flight this year. 
Via The Motley Fool
AI-Focused Drug Discovery Stocks Index Up 26% In December
With the promise of lower costs and shorter development timelines, AI-enabled drug discovery holds massive potential to increase the accessibility of drugs and to treat presently incurable conditions. 
Via Talk Markets
AbCellera to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
From AbCellera Biologics Inc.
Via Business Wire
AI-Focused Drug Discovery Stocks Index Up 10.6% Last Week
A new study concludes that the AI method of drug discovery is up to 250 times more efficient than the traditional method. 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Earnings Preview: AbCellera Biologics
Via Benzinga
AI Meets Biotech: 3 Top Stocks Transforming Medical Science
The AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
The 10 Stocks Using AI To Develop New Drugs Were Up 4%, On Average, Last Week
If, as Morgan Stanley postulates, a $50 billion AI drug discovery revolution is underway, here are 10 publicly-traded micro- and small-cap clinical stage pharma companies that are embracing AI to... 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Micro/Small Cap Companies Using AI In Drug Discovery Up 35% In November
The AI method is up to 250 times more efficient than the traditional method of drug discovery. reducing timelines for drug discovery, increasing accuracy of efficacy and safety predictions. 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023
From AbCellera Biologics Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
AbCellera Biologics (ABCL) Q3 2023 Earnings Call Transcript
ABCL earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
AbCellera Reports Q3 2023 Business Results
From AbCellera Biologics Inc.
Via Business Wire
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
From AbCellera Biologics Inc.
Via Business Wire
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
Multi-year collaboration to jointly discover, develop, and commercialize novel oncology medicines for up to five programs, with the first ADC program focusing on a SMARCA degrader 
From Prelude Therapeutics, Inc.; AbCellera
Via GlobeNewswire
AbCellera to Present at the Jefferies London Healthcare Conference on November 14, 2023
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Announces Two T-Cell Engager Presentations at SITC 2023
From AbCellera Biologics Inc.
Via Business Wire
Argenx's 28% Surge & Promising Product Propel Investor Confidence
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target. 
Via MarketBeat
AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology
From AbCellera Biologics Inc.
Via Business Wire
Why AbCellera Biologics Is Still A Buy Despite Dropping Royalties: Analyst On Long-Term Prospects
Benchmark analyst Robert Wasserman reiterated a Buy rating on AbCellera Biologics Inc. (NASDAQ: ABCL),  
Via Benzinga
3 AI Stocks You’ll Regret Not Buying Soon
AI will have a big impact on biotech, which could help with drug discovery and create opportunities for these top AI stocks to invest in. 
Via InvestorPlace
Why ResMed Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Missfresh Limited (NASDAQ: MF) jumped 168% to $1.38 after the company announced entry of share purchase agreements for financing and business acquisition. 
Via Benzinga
Apple, Fortinet, Microchip Technology And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures traded higher this morning on Friday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
AbCellera Biologics (ABCL) Q2 2023 Earnings Call Transcript
ABCL earnings call for the period ending June 30, 2023. 
Via The Motley Fool
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
AbCellera Reports Q2 2023 Business Results
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Announces that the U.S. Patent Trial and Appeal Board Has Denied Berkeley Lights’ Request for Rehearing
From AbCellera Biologics Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.